| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000026173 |
| Receipt No. | R000030071 |
| Scientific Title | Early anti-VEGF Therapy Intervention for Retinal Vein Occlusion |
| Date of disclosure of the study information | 2017/02/16 |
| Last modified on | 2020/02/19 (Ver. 5) |
| Basic information | ||
| Public title | Early anti-VEGF Therapy Intervention for Retinal Vein Occlusion | |
| Acronym | Early anti-VEGF Therapy Intervention for RVO
|
|
| Scientific Title | Early anti-VEGF Therapy Intervention for Retinal Vein Occlusion | |
| Scientific Title:Acronym | Early anti-VEGF Therapy Intervention for RVO
|
|
| Region |
|
|
| Condition | ||
| Condition | Retinal vein occlusion | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To assess efficacy of early anti-VEGF intervention for retinal vein occlusion |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | Mean change from baseline best corrected visual acuity and macular retinal sensitivity at month 12. |
| Key secondary outcomes | Mean number of intravitreal injection at month 12.
Mean change from baseline central retinal thickness (CRT) at month 12. Mean change from baseline best corrected visual acuity and macular retinal sensitivity at month 6. ocular serious adverse event. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Symptomatic retinal vein occlusion with best corrected visual acuity of 20/40 or better, at least 3 months before enrollment. | |||
| Key exclusion criteria | 1. prior laser treatment, surgery, local steroid injection or anti-VEGF drug administration
2. bilateral retinal vein occlusion 3. uncontrolled glaucoma 4. uncontrolled systemic hypertension 5. other retinal disorders |
|||
| Target sample size | 50 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kyoto Prefectural University of Medicine | ||||||
| Division name | Ophthalmology | ||||||
| Zip code | |||||||
| Address | 465 kajii-cho, Kamigyo-ku, Kyoto | ||||||
| TEL | 075-251-5578 | ||||||
| kenkojim@koto.kpu-m.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kyoto Prefectural University of Medicine | ||||||
| Division name | Ophthalmology | ||||||
| Zip code | |||||||
| Address | 465 kajii-cho, Kamigyo-ku, Kyoto | ||||||
| TEL | 075-251-5578 | ||||||
| Homepage URL | |||||||
| kenkojim@koto.kpu-m.ac.jp | |||||||
| Sponsor | |
| Institute | Kyoto Prefectural Univerisity of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Bayer |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | none |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000030071 |